Goldman Sachs Amends Vincerx Pharma Stake (SC 13G/A)
Ticker: VINC · Form: SC 13G/A · Filed: Feb 5, 2024 · CIK: 1796129
| Field | Detail |
|---|---|
| Company | Vincerx Pharma, Inc. (VINC) |
| Form Type | SC 13G/A |
| Filed Date | Feb 5, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**Goldman Sachs just updated its Vincerx Pharma holdings, signaling a change in their passive investment.**
AI Summary
Goldman Sachs Group Inc. filed an amended SC 13G/A on February 5, 2024, indicating a change in their ownership of Vincerx Pharma, Inc. common stock as of December 29, 2023. This filing, an amendment to a previous disclosure, signals that Goldman Sachs continues to hold a significant, but potentially altered, passive investment in Vincerx Pharma. For current or prospective Vincerx Pharma shareholders, this matters because large institutional holdings can influence stock stability and investor confidence, and any changes in these holdings are closely watched.
Why It Matters
This filing shows that a major financial institution, Goldman Sachs, has updated its reported ownership in Vincerx Pharma, which can impact investor perception and potentially the stock's trading dynamics.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institution, indicating a passive investment, which typically carries low immediate risk.
Analyst Insight
A smart investor would note Goldman Sachs' continued, albeit potentially adjusted, passive stake in Vincerx Pharma, but would not make investment decisions based solely on this routine amendment. Further due diligence on Vincerx Pharma's fundamentals and other institutional holdings would be prudent.
Key Numbers
- 92731L106 — CUSIP Number (identifies Vincerx Pharma, Inc. Common Stock.)
- 0000769993-24-000048 — Accession Number (unique identifier for this specific SEC filing.)
Key Players & Entities
- Goldman Sachs Group Inc. (company) — the entity filing the SC 13G/A, reporting its ownership in Vincerx Pharma, Inc.
- Vincerx Pharma, Inc. (company) — the subject company whose common stock is being reported on.
- December 29, 2023 (date) — the date of the event which required the filing of this statement.
- February 5, 2024 (date) — the date the SC 13G/A filing was made.
- $0.0001 (dollar_amount) — the par value per share of Vincerx Pharma, Inc. Common Stock.
Forward-Looking Statements
- Goldman Sachs will maintain a passive investment strategy in Vincerx Pharma. (Goldman Sachs Group Inc.) — high confidence, target: Next 12 months
- Vincerx Pharma's stock price will experience minimal immediate impact from this routine amendment. (Vincerx Pharma, Inc.) — medium confidence, target: Next 1 week
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under the Securities Exchange Act of 1934.
Who is the 'subject company' in this filing?
The subject company is Vincerx Pharma, Inc., with a Central Index Key (CIK) of 0001796129 and a business address of 260 Sheridan Avenue, Suite 400, Palo Alto, CA 94306.
Who is the 'filed by' entity in this document?
The filing entity is Goldman Sachs Group Inc., with a Central Index Key (CIK) of 0000886982 and a business address of 200 West Street, New York, NY 10282.
What is the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement is December 29, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 5, 2024 regarding Vincerx Pharma, Inc. (VINC).